Loading
Life sciences · Journal article
Current Cardiovascular Risk Reports · September 26, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Purpose of Review Immunotherapies have revolutionized treatment strategies for cancer patients, improving the prognosis in many populations with advanced malignancies. Immune check point inhibitors (ICI) and Chimeric antigen receptor (CAR) T cell therapy are being increasingly used. As the real-world use of immunotherapies increases and indications expand, an understanding of potential cardiovascular toxicities is required. Recent Findings Arrhythmias are among the top reasons for seeking cardiovascular care in immunotherapy treated patients. ICI and CART therapies have been associated with arrhythmias with wide range of estimates reported in randomized clinical trials and retrospective studies. The pathophysiology and risk factors behind ICI and CART therapies is unclear. Summary In this review, we summarize the incidence, mechanisms, risk factors, impact on patient outcomes and management of ICI and CAR-T cell therapy-associated arrhythmia complications.